Congresses

 

The below Genentech/Roche-sponsored congress posters and oral presentations include data presented at scientific meetings from mid-2019 onwards. Click the below links for congress publications of interest.

Emicizumab prophylaxis for the treatment of people with moderate or mild hemophilia A without factor VIII inhibitors: Results from the primary analysis of the HAVEN 6 study

Hermans C, Negrier C, Lehle M, et al. ISTH 2022; Oral presentation 30.5.

Real-world persistence with and adherence to emicizumab prophylaxis in people with hemophilia A –Results from two secondary claims database analyses

Khairnar R, Meyer C, Schuldt R, et al. WFH 2022; Oral presentation 1122212.

Involvement in care decisions and community engagement of people with hemophilia in Europe: Insights from the CHESS II study

Zhang H, Nissen F, Grazzi E, et al. WFH 2022; Poster presentation 1158506.

Analysis of F8 genotypes and pharmacodynamic and safety biomarkers in people with moderate or mild hemophilia A receiving emicizumab in the HAVEN 6 trial

Kiialainen A, Negrier C, Pipe SW, et al. ISTH 2022; Poster presentation 0671.

Bleed outcomes in the moderate and mild hemophilia A population without prophylactic treatment in CHESS II and CHESS PAEDs

Khair K, Nissen F, Ferri-Grazzi E, et al. ISTH 2022; Poster presentation 0670.

Annualized bleed rates in severe Hemophilia A after switch to emicizumab based on CHESS II data, including an oversample of emicizumab patients

Mancuso ME, Nissen F, Zhang H, et al. ISTH 2022; Poster presentation 0674.

Low immunogenicity of emicizumab in persons with haemophilia A

Schmitt C, Emrich T, Asikanius E, et al. EAHAD 2021; Poster presentation ABS141.

Safety and efficacy of emicizumab in persons with haemophilia A with/without FVIII inhibitors: Pooled data from four phase III studies (HAVEN 1–4)

Callaghan MU, Négrier C, Paz-Priel I, et al. EAHAD 2021; Poster presentation ABS192.

Evaluating the economic burden associated with problem joints, across moderate and severe haemophilia A, in children and adults: CHESS Paediatrics and CHESS II

Chowdary P, Hermans C, Asghar S, et al. EAHAD 2021; Poster presentation ABS1148.

Factor VIII use in the treatment of breakthrough bleeds in persons with hemophilia A without inhibitors on emicizumab prophylaxis: The phase III HAVEN 3 study experience

Callaghan M, Trzaskoma B, Ko RH, et al. HFA 2020; Poster presentation.

Improvement in annualized bleed rate in patients with hemophilia A initiating emicizumab – physician reported outcomes from the Adelphi Hemophilia A Disease Specific Programme

Khairnar R, Decker-Palmer M, Mellor J, et al. ASH 2021; Poster presentation 1961.

Characterizing mild and moderate hemophilia A patients in the real world: A patient-centric approach

Witkop M, Xu T, Hanson G, et al. ASH 2021; Poster presentation 2107.

Evaluation of the safety of emicizumab prophylaxis in persons with hemophilia A: An updated summary of thrombotic events and thrombotic microangiopathies

Howard M, McKinley D, Sanabria F, et al. ASH 2021; Poster presentation 3186.

A novel methodology for building longitudinal, patient-centric real world datasets in hemophilia A

Skinner MW, Hanson G, Xu T, et al. ASH 2021; Oral presentation 594.

Emicizumab prophylaxis in persons with hemophilia A, aged ≥50 years, with comorbidities – pooled data from four phase III studies (HAVEN 1, 3, and 4, and STASEY)

Jiménez-Yuste V, Oldenburg J, Tzeng E, et al. ASH 2021; Poster presentation 2103.

Changes in healthcare resource use and costs after emicizumab initiation for hemophilia A

Mahajerin A, Khairnar R, Meyer CS, et al. AMCP Nexus 2020; Poster presentation.

Efficacy/safety in children on 2/4-weekly emicizumab prophylaxis: 52-week outcomes in HAVEN 2

Young G, Sidonio R, Oldenburg J, et al. ASPHO 2022; Poster presentation P010.

Changes in healthcare resource use and costs after emicizumab initiation for hemophilia A

Mahajerin A, Khairnar R, Meyer CS, et al. NHF 2020; Poster presentation.

An early view analysis of characteristics of persons with hemophilia Atreated with emicizumab using secondary claims data

Mahajerin A, Yang E, Patel AM, et al. AMCP 2020; Poster presentation.

Emicizumab prophylaxis for the treatment of infants with severe hemophilia A without factor VIII inhibitors: An interim analysis of the HAVEN 7 study

Pipe S, Collins P, Dhalluin C, et al. EAHAD 2023; Oral presentation LCTR01.

Bone and joint health markers in persons with hemophilia A treated with emicizumab in HAVEN 3

Kiialainen A, Niggli M, Kempton C, et al. ASH 2019; Oral presentation.

Effectiveness of emicizumab under real-world conditions in patients of all ages with hemophilia A with and without FVIII inhibitors: Interim analysis of the non-interventional study EMIIL

Oldenburg J, Escuriola-Ettingshausen C, Fontana P, et al. ISTH 2023; Oral presentation 43.4.

Emicizumab prophylaxis for the treatment of infants with severe hemophilia A without factor VIII inhibitors: Results from the interim analysis of the HAVEN 7 study

Pipe SW, Collins P, Dhalluin C, et al. ASH 2022; Oral presentation 187.

Emicizumab prophylaxis in infants with severe hemophilia A without factor VIII inhibitors: Results from the primary analysis of the HAVEN 7 study

Pipe S, Collins P, Dhalluin C, et al. ASH 2023; Oral presentation 505.

Early patient experiences with emicizumab in the United States: a qualitative study

Markowitz JT, Patel AM, Raimundo K, et al. HFA 2020; Poster presentation.

Emicizumab prophylaxis in people with mild or moderate haemophilia A without factor VIII inhibitors: Results from the interim analysis of the HAVEN 6 study

Negrier C, Mahlangu J, Lehle M, et al. EAHAD 2022; Oral presentation OR002.

Complications associated with central venous acceess devices in patients with hemophilia A: a secondary claims-base analysis

Orji C, Khairnar R, Patel AM, et al. ISPOR 2020; Poster Presentation.

Summary of thromboembolic (TE) or thrombotic microangiopathy (TMA) events in persons taking emicizumab

Lee L, Moreno K, Kuebler P, et al. EAHAD 2020; Oral presentation P131.

Final analysis of the STASEY trial: a single-arm, multicenter, open-label, Phase III clinical trial evaluating the safety and tolerability of emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors

Jiménez-Yuste V, Peyvandi F, Klamroth R, et al. ISTH 2021; Poster presentation PB0521.

Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors

Santagostino E, Oldenburg J, Chang T, et al. ISTH 2019; Oral presentation OC 60.1.

Real-world treatment patterns, health outcomes, and healthcare resource use among persons with hemophilia A

Caplan EO, Patel AM, DeClue R, et al. NHF 2020; Poster presentation 15.

An insight into clinical outcomes in mild, moderate, and severe hemophilia A (HA): A preliminary analysis of the CHESS II study

Nissen F, Burke T, Asghar S, et al. ISTH 2020; Oral presentation OC 09.3.

Effect of moderate and severe hemophilia A on daily life in children and their caregivers: A CHESS Paediatrics Study analysis

Khair K, Nissen F, Silkey M, et al. ASH 2020; Oral presentation 147.

Emicizumab prophylaxis in persons with mild or moderate hemophilia A: Results from the interim analysis of the HAVEN 6 study

Négrier C, Mahlangu J, Lehle M, et al. ASH 2021; Oral presentation 343.

Real-world safety of emicizumab: Interim analysis of the European Haemophilia Safety Surveillance (EUHASS) Database

Nissen F, Jiang Y, Hiew HJ, et al. ASH 2022; Oral presentation 192.

Characteristics and bleeding behavior of females with mild hemophilia A: Longitudinal study from PicnicHealth hemophilia A database

Weyand AC, Hiew HJ, Jiang Y, et al. ASH 2022; Oral presentation 27.

Real-world outcomes of emicizumab in hemophilia A with or without FVIII inhibitors from the Canadian Hemophilia Bleeding Disorder Registry

Poon MC, Lee A, Germini F, et al. ASH 2022; Poster presentation 3796.

Characteristics and healthcare utilization of patients with mild or moderate hemophilia A in the US - an analysis from the PicnicHealth cohort

Sharathkumar A, Jiang Y, Hiew HJ. ASH 2022; Poster presentation 1170.

Patient-reported outcomes among adults with hemophilia A on prophylactic treatment

Chupka J, Palmer MD, Lin CW, et al. ASH 2022; Poster presentation 4894.

Pharmacodynamic biomarkers in infants with hemophilia A receiving emicizumab in HAVEN 7

Kiialainen A, Pipe S, Fijnvandraat K, et al. ASH 2023; Poster presentation 1238.

Emicizumab treatment is efficacious and well tolerated long term in persons with haemophilia (PwHA) with or without FVIII inhibitors: Pooled data from four HAVEN studies

Callaghan M, Negrier C, Paz-Priel I, et al. ISTH 2019; Oral presentation OC 60.2.

 

Emicizumab prophylaxis improves acute and chronic pain-related outcomes in people with haemophilia A (PwHA): Post hoc analysis of 470 patients from HAVEN 1, 3, 4 and STASEY

Hermans C, Skinner MW, Gentile B, et al. EAHAD 2023; Poster presentation PO107.

Estimating the risk of myocardial infarction in persons with hemophilia A using a machine-learning approach with US claims data

Faghmous I, Flores C, Sarouei K, et al. ASH 2019; Poster presentation P-1133.

Comparison of quality of life and bleeding phenotypes in people with congenital hemophilia A: Longitudinal study from the PicnicHealth database of PROMIS®-29 v2.0 scores

Scrimshire J, Roumpanis S, Aizenas M, et al. ISTH 2023; Poster presentation PB1243.

Cost-effectiveness of emicizumab vs efanesoctocog alfa, standard half life (SHL) and other extended half life (EHL) FVIII products for prophylaxis in people with severe hemophilia A without inhibitors

Curtis R, Decker-Palmer M, Wilson MR, et al. ASH 2023; Poster presentation 5053.

Emicizumab prophylaxis in people with haemophilia A (PwHA), aged ≥50 years, with comorbidities – Pooled data from four phase III studies (HAVEN 1, 3, and 4, and STASEY)

Jiménez-Yuste V, Oldenburg J, Tzeng E, et al. EAHAD 2022; Poster presentation PO053.

Patient access to hemophilia A treatment varies across US commercial health plans

Margaretos NM, Patel AM, Pranzer AD, et al. ISPOR 2020; Poster presentation.

Timing of treated spontaneous bleeding in persons with haemophilia A receiving emicizumab prophylaxis 6 mg/kg once every 4 weeks

Pipe SW, Ko RH, Chang T, et al. EAHAD 2020; Poster presentation P191.

Association of physical activity with bleeding frequency in children with hemophilia A: a CHESS PAEDs study analysis

Ofori-Asenso R, Nissen F, Silkey M, et al. ISTH 2021; Poster presentation PB0512.

An analysis of fatalities in persons with congenital hemophilia A reported in the FDA Adverse Event Reporting System (FAERS) database

De Ford C, Kuebler P, Shang A, et al. NHF 2020; Poster presentation 25.

Surgical experience from the Phase III STASEY trial of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors: Data from the second interim analysis

Castaman G, Kremer Hovinga JA, Schutgens R, et al. ISTH 2020; Poster presentation PB0939.

Real-world persistence with and adherence to emicizumab prophylaxis in persons with hemophilia A: a secondary claims database analysis

Mahajerin A, Khairnar R, Meyer CS, et al. ASH 2020; Poster presentation 866.

Emicizumab outcomes in hemophilia A using real-world data from the Canadian Hemophilia Bleeding Disorder Registry

Poon M-C, Lee A, Germini F, et al. ASH 2021; Oral presentation 347.

Evaluation of the safety of emicizumab prophylaxis in people with haemophilia A: An updated summary of thrombotic events and thrombotic microangiopathies

Koparkar S, Barlera F, Nissen R, et al. EAHAD 2023; Poster presentation PO123.

Factor VIII use in the treatment of breakthrough bleeds in hemophilia A patients without inhibitors on emicizumab prophylaxis: the phase 3 HAVEN 3 study experience

Callaghan M, Trzaskoma B, Ko RH, et al. ASH 2019; Poster presentation P-2395.

Quality of life in females and males with mild congenital hemophilia A: Longitudinal study from the PicnicHealth database of PROMIS®-29 v2.0 scores

Weynard AC, Nissen F, Roumpanis S, et al. ISTH 2023; Poster presentation PB1250.

Experience with emicizumab among people with hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry

Poon MC, Lee A, Germini F, et al. ASH 2023; Poster presentation 1240.

A survey study of hematologists in the United States to understand disease management of patients with hemophilia A treated with emicizumab

Owens WE, Patel AM, Poulos K, et al. EAHAD 2020; Poster presentation P205.

Emicizumab in obese adults with hemophilia A - pooled data from three Phase III studies (HAVEN 1, 3 and 4)

Recht M, Mahlangu J, Minhas M, et al. ISTH 2021; Poster presentation PB0435.

A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): Interim analysis results

Jiménez-Yuste V, Klamroth R, Castaman G, et al. ISTH 2019; Oral presentation OC 60.3.

A contemporary framework for understanding mortality in people with congenital hemophilia A (PwcHA)

Pipe SW, Kruse-Jarres R, Mahlangu JN, et al. NHF 2020; Poster presentation 23.

Pharmacokinetics and coagulation biomarkers in persons with hemophilia A (PwHA) and FVIII inhibitors receiving emicizumab in the Phase IIIb STASEY study

Kiialainen A, Petry C, Jiménez-Yuste V, et al. ISTH 2020; Poster presentation PB0942.

A phase IV, multicenter, open-label study of emicizumab prophylaxis in persons with hemophilia A with or without FVIII inhibitors undergoing minor surgical procedures

Escobar M, Dunn A, Quon D, et al. ASH 2020; Poster presentation 1786.

Surgical experience from the phase III STASEY trial of emicizumab prophylaxis in persons with hemophilia A with FVIII inhibitors: Final analysis

Castaman G, Windgya J, Alzahrani H, et al. ASH 2021; Oral presentation 344.

Long-term outcomes with emicizumab prophylaxis for severe haemophilia A without FVIII inhibitors: Efficacy and safety analyses from HAVEN 3 & 4

Mahlangu J, Jiménez-Yuste V, Ventriglia G, et al. EAHAD 2023; Poster presentation PO135.

Estimating the burden of intracranial hemorrhage in persons with hemophilia A using administrative claims data.

Mahajerin A, Patel AM, Yang E, et al. ASH 2019; Poster presentation P-2398.

Quality of life in patients & caregivers living with hemophilia A without inhibitors in Spain, interim analysis of the HEMOLife study

Alvarez-Román MT, Soto I, Garcia M, et al. ISTH 2023; Poster presentation PB0684.

Factor VIII use in the treatment of breakthrough bleeds in people with moderate or mild hemophilia A without factor VIII inhibitors receiving emicizumab prophylaxis: The phase III HAVEN 6 experience

Jiménez-Yuste V, Lim E, Mistry K, et al. ASH 2023; Poster presentation 3999.

Joint bleeds in paediatric patients with haemophilia A: A CHESS study analysis

Castro FA, Silkey M, Khair K, et al. ISTH 2019; Oral presenation OC 70.1.

Characteristics of persons with hemophilia A treated with emicizumab with or without factor VIII inhibitors

Mahajerin A, Yang E, Patel AM, et al. NHF 2020; Poster presentation 31.

Associations between physical activity levels and bleeding frequency in people with mild, moderate, and severe hemophilia A (HA): A preliminary analysis of the CHESS II study

Nissen F, Burke T, Asghar S, et al. ISTH 2020; Poster presentation PB0943.

Analysis of hemophilia A outcomes and treatment patterns using real-world data from the Canadian Hemophilia Bleeding Disorder Registry

Lee A, Germini F, Poon M, et al. ASH 2020; Poster presentation 1793.

Association of hemophilia A inhibitor status and patient-reported outcomes with work productivity and health-related quality of life

Ullman MM, Manco-Johnson MJ, Roberts JC, et al. ASH 2021; Poster presentation 4069.

Management of bleeding in people with hemophilia A on prophylaxis with emicizumab in emergency situations: Recommendations from a Spanish Expert Panel

Jiménez Yuste V, Alvarez-Román MT, Berrueco Moreno R, et al. ISTH 2023; Poster presentation PB0696.

Analytical performance evaluation of a dedicated calibrator and controls for emicizumab quantification

Ramamurthy N, Kucharski C, McInerney M, et al. ISTH 2019; Oral presentation OC 07.4.

A systematic review of mortality statistics and causes of death in people with congenital hemophilia A (PwcHA)

Hay CR, Nissen F, Pipe SW. NHF 2020; Poster presentation 32.

Long-term safety and efficacy for up to >5 years in a phase 1/2 study in patients with severe hemophilia A

Shima A, Nagao A, Taki M, et al. ISTH 2020; Poster presentation PB0950.

Safety and efficacy of emicizumab in persons with hemophilia A with or without FVIII inhibitors: pooled data from four phase III studies (HAVEN 1–4)

Callaghan MU, Négrier C, Paz-Priel I, et al. ASH 2020; Poster presentation 1800.

Trends in prescribing practices for management of hemophilia

Curtis R, Roberts JC, Crook N, et al. ASH 2021; Oral Presentation 2112.

Early patient experiences with emicizumab in the United States: a qualitative study

Markowitz JT, Patel AM, Raimundo K, et al. ISTH 2019; Poster presentation PB0244.

Summary of thrombotic events or thrombotic microangiopathy events in persons taking emicizumab

Lee L, Moreno K, Kuebler P, et al. NHF 2020; Poster presentation 35.

A randomized, multicenter, open-label, Phase III clinical trial to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in persons with hemophilia A in the Asia-Pacific region (HAVEN 5)

Wang S, Zhao X, Wang X, et al. ISTH 2020; Poster presentation PB0957.

Problem joints and their clinical and humanistic burden in children and adults with moderate and severe hemophilia A: CHESS Paediatrics and CHESS II

McLaughlin P, Hermans C, Asghar S, et al. ASH 2020; Poster presentation 2532.

Comparison of a projected hemophilia A population residing in hospital referral regions with and without hemophilia treatment centers in the United States

Santaella MEE, Raimundo K, Schuldt R, et al. ASH 2023; Poster presentation 3696.

Evaluating patient and caregiver treatment preferences in hemophilia A using a discrete choice experiment

Benton M, Shi L, Patel AM, et al. ISTH 2019; Poster presentation PB0245.

Bone and joint health markers in persons with hemophilia A (PwHA) treated with emicizumab in the HAVEN 3 clinical trial

Kiialainen A, Niggli M, Kempton C, et al. NHF 2020; Poster presentation 36.

Second interim analysis results from the STASEY trial: A single-arm, multicenter, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in people with hemophilia A (PwHA) with FVIII inhibitors.

Jiménez-Yuste V, Klamroth R, Castaman G, et al. ISTH 2020; Poster presentation PB0958.

Real-world safety of emicizumab: The first interim analysis of the European Haemophilia Safety Surveillance (EUHASS) Database

Shang A, Bienz NS, Gadiraju R, et al. ASH 2020; Poster presentation 2685.

Physical activity, bleedings and quality of life in patients with haemophilia A without inhibitors - A multicenter, observational Italian study with a wearable device

Mancuso ME, Biasoli C, Marino R, et al. ASH 2023; Oral presentation 663.

Health-related quality of life in paediatric patients with haemophilia A

Castro FA, Silkey M, Khair K, et al. ISTH 2019; Poster presentation PB0250.

An insight into the impact of hemophilia A on daily life according to disease severity: A preliminary analysis of the CHESS II study

Noone D, Nissen F, Xu T, et al. ASH 2020; Poster presentation 3449.

Exposure–response modeling of emicizumab for the prophylaxis of bleeding in haemophilia A patients with and without inhibitors against factor VIII

Jonsson F, Schmitt C, Petry C, et al. ISTH 2019; Poster presentation PB0325.

Impact of hemophilia A inhibitor on joint health and health-related quality of life from the Hemophilia Utilization Group Studies Part VIII in the US

Ullmann MM, Manco-Johnson MJ, Roberts JC, et al. ASH 2020; Poster presentation 3457.

Timing of treated spontaneous bleeding in persons with haemophilia A (PwHA) in the HAVEN 3 study

Mahlangu J, Oldenburg J, O'Connell N, et al. ISTH 2019; Poster presentation PB0694.

Emicizumab prophylaxis improves long-term physical health scores in persons with haemophilia A (PwHA) with and without inhibitors: update from the HAVEN 3 and HAVEN 4 studies

Skinner M, Negrier C, Paz-Priel I, et al. ISTH 2019; Poster presentation PB0698.

Treatment patterns and outcomes in persons with hemophilia A (PwHA): Analysis from the CHOICE survey in the United States

Patel AM, Cyhaniuk A, Raimundo K, et al. ISTH 2019; Poster presentation PB1404.

Emicizumab pediatric experience in clinical studies and beyond

Levy G. WFH 2020; Oral Presentation.